Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 775

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

Epidemiology of Renal Cell Carcinoma: 2022 Update

Bukavina, Laura, Bensalah, Karim, Bray, Freddie, Carlo, Maria, Challacombe, Ben, Karam, Jose A., Kassouf, Wassim, Mitchell, Thomas, Montironi, Rodolfo, O'Brien, Tim, Panebianco, Valeria, Scelo, Ghislaine, Shuch, Brian, van Poppel, Hein, Blosser, Christopher D., Psutka, Sarah P.·2022·European Urology

Abstract

CONTEXT International variations in the rates of kidney cancer (KC) are considerable. An understanding of the risk factors for KC development is necessary to generate opportunities to reduce its incidence through prevention and surveillance. OBJECTIVE To retrieve and summarize global incidence and mortality rates of KC and risk factors associated with its development, and to describe known familial syndromes and genetic alterations that represent biologic risk factors. EVIDENCE ACQUISITION A systematic review was conducted via Medline (PubMed) and Scopus to include meta-analyses, reviews, and original studies regarding renal cell carcinoma, epidemiology, and risk factors. EVIDENCE SYNTHESIS Our narrative review provides a detailed analysis of KC incidence and mortality, with significant variations across time, geography, and sex. In particular, while KC incidence has continued to increase, mortality models have leveled off. Among the many risk factors, hypertension, obesity, and smoking are the most well established. The emergence of new genetic data coupled with observational data allows for integrated management and surveillance strategies for KC care. CONCLUSIONS KC incidence and mortality rates vary significantly by geography, sex, and age. Associations of the development of KC with modifiable and fixed risk factors such as obesity, hypertension, smoking, and chronic kidney disease (CKD)/end-stage kidney disease (ESKD) are well described. Recent advances in the genetic characterization of these cancers have led to a better understanding of the germline and somatic mutations that predispose patients to KC development, with potential for identification of therapeutic targets that may improve outcomes for these at-risk patients. PATIENT SUMMARY We reviewed evidence on the occurrence of kidney cancer (KC) around the world. Currently, the main avoidable causes are smoking, obesity, and high blood pressure. Although other risk factors also contribute, prevention and treatment of these three factors provide the best opportunities to reduce the risk of developing KC at present.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2022.08.019

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 117 references

Research works printed but not linked: 21

  1. Turner, 2017, Epidemiology of the small renal mass and the treatment disconnect phenomenon, Urol Clin North Am, 44, 147, 10.1016/j.ucl.2016.12.001 · doi:10.1016/j.ucl.2016.12.001
  2. Clague, 2009, Sensitivity to NNKOAc is associated with renal cancer risk, Carcinogenesis, 30, 706, 10.1093/carcin/bgp045 · doi:10.1093/carcin/bgp045
  3. Kim, 2021, A systematic review and meta-analysis of the significance of body mass index on kidney cancer outcomes, J Urol, 205, 346, 10.1097/JU.0000000000001377 · doi:10.1097/ju.0000000000001377
  4. Alcala, 2022, The relationship between blood pressure and risk of renal cell carcinoma, Int J Epidemiol, 51, 1317
  5. Shebl, 2012, Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study, BMC Nephrol, 13, 65, 10.1186/1471-2369-13-65 · doi:10.1186/1471-2369-13-65
  6. Moore, 2016, Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA, Intern Med, 176, 816
  7. Gorsky, 1988, The mortality, morbidity, and economic costs of alcohol abuse in New Hampshire, Prev Med, 17, 736, 10.1016/0091-7435(88)90092-8 · doi:10.1016/0091-7435(88)90092-8
  8. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004, Some drinking-water disinfectants and contaminants, including arsenic. Monographs on chloramine, chloral and chloral hydrate, dichloroacetic acid, trichloroacetic acid and 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone, IARC Monogr Eval Carcinog Risks Hum, 84, 269
  9. Vlaanderen, 2013, Occupational exposure to trichloroethylene and perchloroethylene and the risk of lymphoma, liver, and kidney cancer in four Nordic countries, Occup Environ Med, 70, 393, 10.1136/oemed-2012-101188 · doi:10.1136/oemed-2012-101188
  10. Andrew, 2022, Kidney cancer risk associated with historic groundwater trichloroethylene contamination, Int J Environ Res Public Health, 19, 618, 10.3390/ijerph19020618 · doi:10.3390/ijerph19020618
  11. Jhuang, 2019, Reduction in the incidence of urological cancers after the ban on Chinese herbal products containing aristolochic acid: an interrupted time-series analysis, Sci Rep, 9, 19860, 10.1038/s41598-019-56394-y · doi:10.1038/s41598-019-56394-y
  12. Liu, 2016, Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical features, treatments and prognosis, PLoS One, 11, e0166897, 10.1371/journal.pone.0166897 · doi:10.1371/journal.pone.0166897
  13. Schmidt, 2004, Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the MET proto-oncogene, J Urol, 172, 1256, 10.1097/01.ju.0000139583.63354.e0 · doi:10.1097/01.ju.0000139583.63354.e0
  14. Hasumi, 2016, Birt-Hogg-Dubé syndrome: clinical and molecular aspects of recently identified kidney cancer syndrome, Int J Urol, 23, 204, 10.1111/iju.13015 · doi:10.1111/iju.13015
  15. Zbar, 2002, Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome, Cancer Epidemiol Biomarkers Prev, 11, 393
  16. Caliò, 2019, MiT family translocation renal cell carcinoma: from the early descriptions to the current knowledge, Cancers, 11, 1110, 10.3390/cancers11081110 · doi:10.3390/cancers11081110
  17. Argani, 2007, Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum, Am J Surg Pathol, 31, 1149, 10.1097/PAS.0b013e318031ffff · doi:10.1097/pas.0b013e318031ffff
  18. Neves JB, Roberts K, Nguyen JS, et al. Succinate dehydrogenase deficient renal cell carcinoma: comprehensive molecular profiling with diagnostic and therapeutic implications. iScience. In press. https://dx.doi.org/10.2139/ssrn.4102630. · doi:10.2139/ssrn.4102630
  19. Argani, 2022, Renal cell carcinoma associated with tuberous sclerosis complex (TSC)/mammalian target of rapamycin (MTOR) genetic alterations, Mod Pathol, 35, 296, 10.1038/s41379-021-00971-y · doi:10.1038/s41379-021-00971-y
  20. Bertolotto, 2016, Corrigendum: a SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma, Nature, 531, 126, 10.1038/nature16158 · doi:10.1038/nature16158
  21. Reig Torras, 2022, Molecular genetic determinants of shorter time on active surveillance in a prospective phase 2 clinical trial in metastatic renal cell carcinoma, Eur Urol, 81, 555, 10.1016/j.eururo.2021.12.003 · doi:10.1016/j.eururo.2021.12.003

Cited by

See all 775

Metadata

Authors
Bukavina, L., Bensalah, K., Bray, F., Carlo, M., Challacombe, B., Karam, J. A., Kassouf, W., Mitchell, T., Montironi, R., O'Brien, T., Panebianco, V., Scelo, G., Shuch, B., van Poppel, H., Blosser, C. D., & Psutka, S. P.
Venue
European Urology
Publisher
Elsevier BV
Published
2022-11
Volume
82
Issue
5
Pages
529-542
ISSN
0302-2838 (ISSN-L)
OpenAlex
W4295752719
Cited by
775
References
117
FWCI
85.69
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiology of Renal Cell Carcinoma: 2022 Update. https://app.cochat.ai/papers/10.1016/j.eururo.2022.08.019
The paper
Bukavina, L., Bensalah, K., Bray, F., Carlo, M., Challacombe, B., Karam, J. A., Kassouf, W., Mitchell, T., Montironi, R., O'Brien, T., Panebianco, V., Scelo, G., Shuch, B., van Poppel, H., Blosser, C. D., & Psutka, S. P. (2022). Epidemiology of Renal Cell Carcinoma: 2022 Update. European Urology. https://doi.org/10.1016/j.eururo.2022.08.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.